This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Randomized Clinical Trial on Supplementation of DHA and AA to Preterm Infants

This study has been completed.
Information provided by:
University of Oslo Identifier:
First received: September 22, 2005
Last updated: February 14, 2007
Last verified: September 2005

A randomized, double-blind trial of docosahexaenoic and arachidonic acid supplementation in breast-fed preterm infants


Docosahexaenoic acid (DHA) and arachidonic acid (AA) are essential for preterm infants. Human milk and preterm formulas contain DHA and AA, but at lower concentrations than required to approximate utero accretion rate.


To evaluate the effect of a high dose DHA and AA supplement to breast-fed preterm infants in the early neonatal period. Primary endpoints are neurodevelopment at 6 and 20 months of age.


A randomized double-blind placebo-controlled study is carried out in four Norwegian neonatal centers.

Subjects and methods:

Infants with birth weight < 1.5 kg are randomized to either an intervention or a control group. All infants receive fortified human milk, and a daily dose of 0.5 ml study oil per 100 ml milk. Infants in the intervention group receive oil with DHA and AA (Formulaid, Martek, USA), while the control oil contains vegetable oil without DHA or AA. Blood samples are collected at birth (cord), and at start and stop of the intervention. Plasma is analyzed for fatty acid pattern using high performance liquid chromatography.

Condition Intervention
Infant, Low Birth Weight Procedure: Supplement of fatty acid (DHA and AA)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University of Oslo:

Primary Outcome Measures:
  • Cognitive development

Secondary Outcome Measures:
  • Growth
  • Adverse events

Estimated Enrollment: 140
Study Start Date: December 2003

Ages Eligible for Study:   up to 1 Month   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Birth weight < 1500 g
  • Born at one of 4 participating neonatal centers in Norway

Exclusion Criteria:

  • Cerebral haemorrhage (stage 3 or 4)
  • Major congenital malformations that are supposed to affect growth and development
  • Illness that require prolonged parenteral nutrition (>4 weeks)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00226187

University of Oslo
Oslo, Norway, 0316
Sponsors and Collaborators
University of Oslo
Study Chair: Christian A Drevon, Dr. Med. University og Oslo
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00226187     History of Changes
Other Study ID Numbers: 1
Study First Received: September 22, 2005
Last Updated: February 14, 2007

Keywords provided by University of Oslo:
Fatty acids
Human milk
Infant development
Very low birthweight infants

Additional relevant MeSH terms:
Birth Weight
Body Weight
Signs and Symptoms processed this record on August 18, 2017